Celularity Inc
CELU
查看详细走势图
1.300USD
+0.130+11.11%
收盘 02/06, 16:00（美东）报价延迟15分钟
36.68M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+11.11%
5天
+6.56%
1月
+4.84%
6月
-60.00%
今年开始到现在
+17.12%
1年
-39.81%
查看详细走势图
TradingKey Celularity Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Celularity Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名109/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Celularity Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Celularity Inc亮点
亮点风险
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
业绩高增长
公司营业收入稳步增长，连续3年增长201.64%
业绩增长期
公司处于发展阶段，最新年度总收入54.22M美元
估值合理
公司最新PE估值-0.39，处于3年历史合理位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值42.00K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.90
分析师目标
根据
1
位分析师
买入
评级
6.000
目标均价
+400.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Celularity Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Celularity Inc简介
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
公司代码CELU
公司Celularity Inc
CEOHariri (Robert J)
网址https://celularity.com/
相关品种
